AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05370378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Release Therapy
Description: 1. Specific muscle will be warmed up by applying heating pad for 10 to 15 minutes.~2. Patient will be positioned prone lying and the therapist will be standing at the side of affected limb.~3. Therapist will apply deep pressure at the area of tenderness while patient will actively move the limb from internal to external rotation repeatedly.~4. This maneuver will take about 15 minutes to complete in one session and will be applied alternatively 3 days a week for two weeks.~5. After this, cold pack is applied and general ROMs and strengthening exercises are performed to prevent soreness
Study NCT04354675 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Automated program (ChatBot)
Description: Pre-test counseling and information through a pre-test automated genetic counseling program (ChatBot)
Study NCT04354675 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genetics counselor
Description: Traditional in-person genetic counseling
Study NCT04354675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCGCKQ Survey
Description: Survey assessing Breast Cancer Genetic Counseling Knowledge Questionnaire (BCGCKQ)
Study NCT04354675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BCGCKQ Survey
Description: Survey assessing Breast Cancer Genetic Counseling Knowledge Questionnaire (BCGCKQ)
Study NCT04354675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction Survey
Description: Survey assessing satisfaction with Decision-Genetic Testing
Study NCT05600114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution
Description: CBD 150 mg BID
Study NCT05600114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution
Description: CBD 300 mg BID
Study NCT05600114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study NCT06207578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant placement using crestal sinus approach
Description: a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision. After flap reflection, the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
Study NCT06207578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement using osseodensification
Description: The implant motor will be adjusted on reverse mode with 800 to 1200 rpm. According to the desired implant dimension, Densah bur diameter will be used and then implant placement.
Study NCT04636138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will exercise on a treadmill three times weekly at approximately 60% VO2max for 30 minutes (week one) followed by 45 minutes (week two and thereafter) for a total of 6 seeks.
Study NCT06081985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation with double-cone coil
Description: Deep Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with double-cone coil
Study NCT06081985 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation with sham coil
Description: Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with sham coil
Study NCT05980507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI201
Description: ICI201 CAR-T cell injection
Study NCT04354675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Satisfaction Survey
Description: Survey assessing satisfaction with Decision-Genetic Testing
Study NCT04354675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genetic testing
Description: Genetic testing for all participants will assess for a mutation in 47 genes commonly associated with hereditary cancer syndromes (Invitae's Common Hereditary Cancer Panel) for those who choose to complete testing.
Study NCT04354675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genetic testing
Description: Genetic testing for all participants will assess for a mutation in 47 genes commonly associated with hereditary cancer syndromes (Invitae's Common Hereditary Cancer Panel) for those who choose to complete testing.
Study NCT06272084 — intervention group
Intervention type: DEVICE
Intervention: Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO
Description: Retrospective Data Analysis of TPE treatments with multiFiltratePRO
Study NCT05602571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT+Exercise
Description: Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught a home exercise program including stretching and eccentric strengthening exercises by an experienced physiotherapist. The eccentric exercises consisted of the following: three sets of 10 repetitions for wrist and elbow ﬂexion; two sets of 10 repetitions for wrist extension strengthening, starting with 50% of maximum strength and density and increasing the resistance each week; and ﬁnally, two sets of 10 repetitions for the wrist ﬂexor and extensor muscle groups comprising 20s of stretching and 10s of relaxing using the unaﬀected hand. Exercise program will be done twice a day for 3 months.
Study NCT05602571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP+ESWT+Exercise
Description: Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged. Approximately 3 cc of the PRP obtained will be applied to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).
Study NCT05602571 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham PRP+ESWT+Exercise
Description: Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~In Sham-PRP group,10 ml of venous blood will be taken and after the same waiting time 3 cc of 0.9% saline will be injected to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).
Study NCT05299996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flexible ureterorenoscopy
Description: stone disintegration stricture dilation tumor resection access guidance
Study NCT05605314 — intervention group
Intervention type: OTHER
Intervention: Cyclosporine
Description: eye drop
Study NCT05814978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Scapular Therapeutic Exercise Group
Description: All subjects will perform a program of scapular therapeutic exercises including: neuromuscular control/strength - scapular therapeutic exercises that leads to, at least, moderate muscular activity levels; and stretching exercises.~The intervention period will be of 8 weeks, considering in-person and/or home sessions.
Study NCT06454448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab;decitabine;
Description: Adebrelimab:1200 mg Decitabine:10mg/m2 or 15mg/m2
Study NCT06152835 — intervention group
Intervention type: OTHER
Intervention: Data and breast milk samples collection
Description: Breast milk samples and, clinical, anamnestic and lifestyle data collection
Study NCT06164496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standart manual toothbrush
Description: Device on plaque removal efficacy
Study NCT06164496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 360 degree toothbrush
Description: Device on plaque removal efficacy
Study NCT05523128 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ZS802
Description: A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor VIII variant. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg.
Study NCT05981417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Therapeutic exercise sessions will be guided by a physiotherapist.
Study NCT05981417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: Therapeutic exercise sessions will be performed at home.
Study NCT06404216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking group training
Description: 16 60-minute NW group sessions, twice weekly. Sessions will be led by a qualified healthcare professional and a graduating student.~A social worker (SP) will participate in one weekly session aiming to empower the participants and utilize group dynamics techniques to promote successful continuation of independent walking following the guided period.~Communication throughout the study will be conducted via a WhatsApp forum, to motivate and sustain regular walking during and after the training period. Following 2 months of guidance the group will be launched independently, while keeping remote contact. Same frequency and schedule will be encouraged.
Study NCT06152978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
Study NCT06515873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: The virtual reality headset, which will display one of the 3 available scenarios, will be placed on the patient head during a surgery under spinal anesthesia.
Study NCT05105750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin 100 mg/d
Description: 100mg aspirin for at least 3 days followed by aspirin 100 mg/d
Study NCT05105750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indobufen 200 mg bid
Description: 100mg aspirin for at least 3 days followed by indobufen 200 mg bid
Study NCT04991727 — intervention group
Intervention type: BEHAVIORAL
Intervention: recruitment maneuvers
Description: Immediately after endotracheal intubation is completed~First RM (pulmonary retraction), maintain pressure at 40cmH2O for 30s, and then~Mechanical ventilation was maintained with 7cmH2O PEEP, and the RMS was repeated every 30 minutes until the end of surgery
Study NCT05774054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid
Description: received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)> 65 mmHg despite adequate fluid resuscitation
Study NCT05774054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: noradrenaline
Description: received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
Study NCT04774536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRISPR_SCD001
Description: CRISPR_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.
Study NCT05482477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation
Description: Transcutaneous electrical acupoint stimulation (TEAS) is a new type of acupoint stimulation therapy that inputs low-frequency pulse current into human acupoints through electrodes pasted on the skin surface to achieve therapeutic purposes, which combined the preponderances of both acupuncture and transcutaneous electrical nerve stimulation (TENS). TEAS is non-invasive, easy to operate and acceptable to patients. Study showed that TEAS treatment can reduce the consumption of intraoperative anesthetic and improve postoperative nausea and vomiting (PONV) and postoperative recovery.
Study NCT05482477 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous acupoint electrical stimulation
Description: Transcutaneous electrical acupoint stimulation (TEAS) is a new type of acupoint stimulation therapy that inputs low-frequency pulse current into human acupoints through electrodes pasted on the skin surface to achieve therapeutic purposes, which combined the preponderances of both acupuncture and transcutaneous electrical nerve stimulation (TENS). TEAS is non-invasive, easy to operate and acceptable to patients. Study showed that TEAS treatment can reduce the consumption of intraoperative anesthetic and improve postoperative nausea and vomiting (PONV) and postoperative recovery.
Study NCT04961541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
Study NCT06407804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrower's Ten Exercise Program
Description: No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 2 sets for 10 repetitions with 1 minute rest between sets.
Study NCT06407804 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Routine physical therapy.
Description: In this, the exercises will be performed in 2 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min Per Session)
Study NCT06510608 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical analysis of saliva sample
Description: It is the examination of saliva samples taken with biochemical methods. In this way, the substances in its content and the concentration of cytokines are analyzed.
Study NCT06152978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
Study NCT06152978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
Study NCT04961541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant
Description: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.
Study NCT04961541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
Description: Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
Study NCT04992065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 A 15 mg
Description: 15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
Study NCT04992065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 A 40 mg
Description: 40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
Study NCT04992065 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo I A (for NNC0385-0434 A 15 mg)
Description: Placebo administered as 1 tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces). placebo tablets are sized match to the active arm within dose level
Study NCT04992065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 A 100 mg
Description: 100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
Study NCT04992065 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo I A (for NNC0385-0434 A 40 mg)
Description: Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level
Study NCT04992065 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo II A (for NNC0385-0434 A 100 mg)
Description: Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level
Study NCT04992065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab 140 mg/mL, Repatha®
Description: Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL
Study NCT05467332 — intervention group
Intervention type: DEVICE
Intervention: HIGH FLOW NASAL OXYGEN
Description: BEFORE EXTUBATION, AN AIRWAY EXCHANGE CATHETER (AEC) WILL BE PUT INTO THE PATIENTS' TRACHEA AND IT WILL REMAIN IN SITE AFTER EXTUBATION. THROUGH AN AEC CONNECTED TO A PRESSURE MONITOR, IT WILL BE RECORDED TRACHEAL PRESSURE DURING SPONTANEOUSLY BREATHING PATIENT AT DIFFERENT FLOW RATES OF HFNC THAT WILL BE APPLIED JUST AFTER EXTUBATION.~MEANWHILE, VITAL PARAMETERS RECORDED WITH A MULTIPARAMETRIC MONITOR WILL BE RECORDED.~FINALLY, MONITORING OF ELECTRICAL ACTIVITY OF DIAPHRAGM WILL BE RECORDED THROUGH A DEDICATED NASOGASTRIC TUBE TO EVALUATE IT AT DIFFERENT FLOW RATES.
Study NCT06233201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India
Study NCT06233201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
Study NCT05352698 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NT ProBNP (Roche)
Description: This NT ProBNP assay is a point-of-care (POC) test that will be conducted on a 2 mL sample of whole blood collected in a non-heparinized tube. NT ProBNP results are used in this setting to predict perioperative cardiovascular risk.
Study NCT04982328 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Th17 cytokine profile
Description: Screening for the components of metabolic syndrome
Study NCT04982328 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for the components of metabolic syndrome
Description: Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
Study NCT04982328 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of the degree of steatosis
Description: The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
Study NCT05227560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary Therapies
Description: The emotional freedom technique was applied to the experimental group.
Study NCT06157996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib and tislelizumab plus CapeOX chemotherapy
Description: Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w + Lenvatinib 8mg, qd po regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.